Xilonix is currently in phase III studies in the United States and Europe for the treatment of colorectal cancer.
Currently, Xilonix, is being evaluated in advanced colorectal cancer patients with cachexia. Cancer cachexia is a term used to describe a syndrome of progressive weight loss, anorexia, and a loss of skeletal muscle mass due to a malignant growth.
Xilonix is being manufactured by XBiotech USA, Inc., a company in Austin, Texas. XBiotech is a leading developer of biological therapies—including the discovery and development of True Human antibodies.
XBiotech is looking to start manufacturing and shipping Xilonix by early 2016.
Xilonix is a "True Human" monoclonal antibody and targets interleukin-alpha1. Xilonix works by stopping the growth of cancer cells.
How was your experience with ?
Xilonix Drug Class
Xilonix is part of the drug class: